Drug Summary
What Is Hernexeos?
Hernexeos (zongertinib tablets) is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
What Are Side Effects of Hernexeos?
Side effects of Hernexeos include:
- diarrhea,
- liver toxicity,
- rash,
- fatigue,
- nausea,
- nail disorders,
- cough,
- shortness of breath,
- musculoskeletal pain,
- upper respiratory tract infections,
- decreased lymphocytes,
- increased alanine aminotransferase,
- increased aspartate aminotransferase,
- decreased potassium, and
- increased gamma glutamyl transferase.
Seek medical care or call 911 at once if you have the following serious side effects:
- Serious eye symptoms such as sudden vision loss, blurred vision,tunnel vision,eye painor swelling, or seeing halos around lights;
- Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;
- Severe headache,confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.
This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.
Dosage for Hernexeos
The recommended dosage of Hernexeos is based on body weight. The recommended dosage of Hernexeos for patients who weigh less than 90 kg is 120 mg. The recommended dosage of Hernexeos for patients who weigh 90 kg or greater is 180 mg.
Take Hernexeos orally once daily with or without food until disease progression or unacceptable toxicity.
Hernexeos In Children
The safety and effectiveness of Hernexeos have not been established in pediatric patients.
What Drugs, Substances, or Supplements Interact with Hernexeos?
Hernexeos may interact with other medicines such as:
- strong CYP3A inducers and
- BCRP substrates.
Tell your doctor all medications and supplements you use.
Hernexeos During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Hernexeos; it may harm a fetus. The pregnancy status of patients who can become pregnant should be verified prior to initiating Hernexeos. Patients who can become pregnant are advised to use effective contraception during treatment with Hernexeos and for 2 weeks after the last dose. It is unknown if Hernexeos passes into breast milk. Because of the potential for serious adverse reactions in breastfed children from Hernexeos, breastfeeding is not advised during treatment with Hernexeos and for 2 weeks after the last dose.Additional InformationOur Hernexeos (zongertinib tablets), for Oral Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.